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Abstract 18 
Background: The functional role of progesterone receptor (PR) signalling was previously 19 
unclear and PR testing in breast cancer is controversial. Recent defining work has highlighted 20 
the functional crosstalk that exists between the oestrogen receptor (ER) and PR. The purpose 21 
of this retrospective cohort study was to compare the prognostic value of the combined 22 
oestrogen receptor (ER) and progesterone receptor (PR) score with either ER or PR alone. 23 
Methods: Tumour Allred ER and PR scores were reclassified as negative, low and high. The 24 
combined endocrine receptor (CER) was calculated as the average of the reclassified ER and 25 
PR scores, resulting in 3 groups: CER negative, impaired and high. Cox proportional hazards 26 
models were used to estimate disease-free survival (DFS) and breast cancer-specific survival 27 
(BCSS). Results: The CER was a more powerful predictor of 5-year DFS and BCSS than 28 
either ER or PR alone. In multivariate analysis that included ER, PR and CER, only CER 29 
remained an independent prognostic variable for 5-years DFS (HR 0.393 CI 0.283-0.548, 30 
P=0.00001) and BCSS (HR 0.553 CI 0.423-0.722, P=2.506 x10
-8
). In ER+ patients impaired 31 
CER was an independent marker of poor outcome for 5-years DFS (HR 2.469 CI 1.049-32 
5.810, P=0.038) and BCSS (HR 1.946 CI 1.054-3.596 P=0.033) in multivariate analysis that 33 
included grade, LN, tumour size, HER 2 status and PR status. The results were validated in a 34 
separate cohort of patients. Conclusion: CER is a more powerful discriminator of patient 35 
outcome than either ER or PR alone. Economical and simple, it can identify risk in ER+ early 36 
breast cancer and potentially be utilised for adjuvant cytotoxic chemotherapy decision-37 
making. 38 
 39 
Keywords 40 
Breast cancer, oestrogen receptor, progesterone receptor, endocrine therapy, combined 41 
endocrine receptor.  42 
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Introduction 43 
Worldwide breast cancer is the most frequently diagnosed cancer in woman. The majority, 44 
approximately 70%, express the oestrogen receptor (ER). ER positive disease (ER+) has 45 
historically been perceived as the ‘lesser of two evils’, yet many women with ER+ breast 46 
cancer still succumb to their disease. Breast cancer is responsible for over 10,000 deaths each 47 
year in the UK [www.cancerresearchuk.org] and remains the leading cause of cancer deaths 48 
among females in less developed countries (Torre et al, 2012). The advent of gene expressing 49 
profiling and multi parametric assays has brought to the fore that ER+ breast cancer is a 50 
heterogeneous disease and highlights the importance of targeted individual treatment 51 
selection (Dowsett et al, 2010; Paik S et al, 2006). For most of the world, these validated 52 
methods to stratify risk and guide treatment decisions are are too expensive and subsequently 53 
not routinely available. As recognised by the St Gallen conference, surrogate markers or less 54 
expensive pathology tests may provide valuable information in such countries (Coates et al, 55 
2015). 56 
Semi-quantitative immunohistochemistry (IHC) is a near universal method of tumour 57 
hormone receptor (ER and progesterone receptor, PR) testing. Tumour ER expression is a 58 
powerful predictor of response to endocrine therapy and its value is undisputed. Until 59 
recently, the biological role of PR was less well defined and it was considered a biomarker of 60 
ER function (Horwitz and McGuire, 1975). ER+/PR+ tumours are associated with better 61 
clinical outcome (Blows et al, 2010; Purdie et al, 2014; Viale et al, 2007) however the 62 
underlying mechanism responsible for this was poorly understood. Recent, defining work has 63 
now elucidated that PR redirects where ER binds to chromatin and acts as a proliferative 64 
brake in ER+ breast cancer (Mohammed H et al, 2015). This highlights the role of functional 65 
crosstalk between both the ER and PR (Mohammed H et al, 2015) and underlines the value 66 
of both ER and PR testing in breast cancer. 67 
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In this study we hypothesised that semi-quantitative IHC ER and PR scores together may 68 
represent a surrogate ‘snap shot’ of functional hormone receptor crosstalk. We therefore 69 
analysed the ER and PR together as a combined endocrine receptor (CER) to test if this 70 
would be more informative of outcome than either factor independently. We report that the 71 
CER is a better predictor of outcome than either the ER or PR, and the CER is an 72 
independent significant prognostic factor. The results were validated in a separate cohort of 73 
breast cancer patients. 74 
  75 
Patients and Methods 76 
Derivation study patient population 77 
1711 female patients were diagnosed with primary operable invasive breast cancer 78 
(symptomatic and screen detected) between October 1995 and September 1998 in Greater 79 
Glasgow NHS hospitals. The Greater Glasgow Breast Cancer (GGBC) database contains 80 
pathological, treatment and follow up details for these patients. Original pathology report 81 
included % tumour cells staining for ER. PR was not routinely tested during this period. 82 
Tumour samples were centrally re-analysed for 557 patients, randomly selected from the 83 
1711 patients (33%) (supplementary figure 1A). All patients in this cohort received 84 
tamoxifen monotherapy for 5 years except for two whose prescribed endocrine agent was not 85 
documented as they were enrolled in the ATAC study. The Research Ethics committee of 86 
North Glasgow University Hospital approved the collection of patient data and use of human 87 
tissue in this study.  88 
 89 
Tissue microarray (TMA) construction and Immunohistochemistry (IHC) 90 
We have previously described the method for the TMA construction using formalin fixed 91 
paraffin embedded (FFPE) tissue, taken at time of surgical resection (Mohammed et al, 92 
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2012a; Mohammed et al, 2012b). Triplicate TMA were constructed to avoid heterogeneity of 93 
PR staining (Mohammed et al, 2012a). The IHC for ER, PR and HER2 was performed as we 94 
described previously (Mohammed et al, 2012a; Mohammed et al, 2012b) applying protocols 95 
established in the CPA accredited diagnostic pathology laboratory, Glasgow Royal Infirmary 96 
with appropriate positive and negative controls.  97 
 98 
IHC scoring 99 
Tumour Allred ER and PR scores were scored as we have previously reported (Mohammed et 100 
al, 2012a). A cut-off to define receptor positivity for ER and PR was an Allred score ≥3, the 101 
internationally accepted cut-off. High scores were defined as Allred 6-8, and low scores as 102 
Allred 3-5. Representative examples of ER and PR staining for each scoring category is 103 
shown in supplementary figure 2. HER2 membrane staining was scored as previously 104 
described (Mohammed et al, 2012b).  105 
 106 
Combined Endocrine receptor (CER) 107 
The Allred ER and PR scores were reclassified. A score of 0 was assigned to an Allred score 108 
of less than 3, 1 assigned to Allred scores 3-5 and 2 assigned to Allred scores 6-8. The CER 109 
was calculated as the average of the reclassified ER and PR scores. CER 0 represents 110 
negative endocrine receptor status, CER 0.5-1.5 represents impaired endocrine receptor status 111 
(CER impaired) and CER 2 represents high endocrine receptor status (CER high).  112 
 113 
Validation study patient population 114 
The validation cohort of patients consisted of a consecutive series of new diagnosed early 115 
invasive female breast cancer patients presenting at two Greater Glasgow Hospitals between 116 
January 2008 and January 2009 (supplementary figure 1B). The Caldicott Guardian granted 117 
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permission for the use of patient data. All patients underwent curative surgery and adjuvant 118 
treatment prescriptions as per national guidelines (SIGN, 2007) were discussed at a post-119 
operative multidisciplinary meeting. ER and PR status for this cohort was obtained from 120 
routine pathology records. 121 
 122 
Follow-up 123 
Follow up data was confirmed with the registrar general and patient case records for the 124 
derivation study patient population included survival status (alive, death other cause and 125 
breast cancer specific death) and documentation of date and site of recurrence (none, local, 126 
regional, distant). For patients who died, the date of death was recorded; all deaths not 127 
attributable to breast cancer were censored at the date of death. The primary outcomes in this 128 
analysis were time from definitive surgery to breast cancer-specific death and time to 129 
recurrence. In addition, early 5-year disease free survival (DFS) was analysed by censoring 130 
events at 5-years. DFS was defined as alive and well with no documented local, regional or 131 
distant breast cancer recurrence or breast cancer specific death. Accordingly, the end points 132 
were breast cancer specific survival (BCSS) and DFS at 5-years. 133 
The validation study patient population follow up was confirmed using electronic case 134 
records. For every patient, details of definitive surgery date and most recent clinical review 135 
date were collected to calculate time to outcome. Clinical review included either breast 136 
surgery follow-up clinic or oncology follow-up clinic. For patients who died, the date of 137 
death was recorded; all deaths not attributable to breast cancer were censored at the date of 138 
death. Patient status at most recent review date was recorded (alive and well, documented 139 
local, regional or distant breast cancer recurrence or breast cancer specific death). The end 140 
point was DFS.  141 
 142 
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Statistical analysis 143 
Statistical analysis was carried out using SPSS version 22. Univariate survival analysis was 144 
performed using Kaplan Meier method analysed by the log-rank test. Calculation of hazard 145 
ratios (HR) for both univariate and multivariate analysis performed using Cox’s proportional-146 
hazards model; a stepwise backward procedure was used to derive a final model of variables 147 
that had a significant independent relationship with patient outcome.  148 
 149 
Results 150 
Derivation study population 151 
A total of 1711 patients presented with operable invasive breast cancer from October 1995 to 152 
September 1998. 557 patient tumour samples were randomly selected for TMA construction 153 
and centrally tested for ER and PR. Male breast cancers were excluded due to their biological 154 
heterogeneity. Accurate follow up data and tumour Allred scores for ER and PR were 155 
available for 90% (n=503) patients. 63% (n=319) were ER+ and 42% (n=210) were 156 
ER+/PR+. Patient and tumour characteristics are detailed in Table 1. Median follow up was 157 
12.7 years, 61% (n=305) patients were alive, 20% (n=102) had died as a result of breast 158 
cancer and 19% (n=96) had died from other causes. At 5-years, 16% (n=82) had a breast 159 
cancer specific event.  160 
 161 
CER scores (0-2) 162 
CER scores (0, 0.5, 1, 1.5, 2) survival analysis confirmed the selected cut-offs (figure 1) 163 
defining the classification of negative (CER 0), impaired (CER 0.5-1.5) and high (CER2). 164 
CER 0 (HR 6.915 CI 3.131-15.264, P=0.000002), CER 0.5 (HR 3.418 CI 1.085-10.771, 165 
P=0.036), CER 1 (HR 2.617 CI 1.044- 6.560, P=0.040) and CER 1.5 (HR 3.031 CI 1.099-166 
8.360, P=0.032) with CER 2 as the indicator category.  167 
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 168 
Redistribution of endocrine response using the CER compared to ER  169 
Of the 319 ER+ patients 263 patients had an Allred ER high (6-8), when the CER was 170 
applied 46% (n=121) of these patients were reclassified as impaired. In addition, 6% (n=12) 171 
of ER negative were reclassified as CER impaired (Table 1).  172 
 173 
CER and patient outcome 174 
The CER classification resulted in a statistically significant difference in both early 5-year 175 
DFS and BCSS between negative, impaired and high categories (figures 2A and 2D). No 176 
statistical difference was demonstrated between ER high and low (figures 2B and 2E) or PR 177 
negative and low (figures 2C and 2F).  178 
 179 
Multivariate analysis 180 
Survival analysis confirmed that tumour grade, tumour size and lymph node (LN) (0 nodes 181 
positive, 1-3 nodes positive and greater than 3 nodes positive) and HER2 positivity were all 182 
predictive of prognosis (data not shown).  183 
The CER was a more powerful predictor of 5-year DFS and BCSS than either the ER or PR 184 
alone. In multivariate analysis that included ER, PR and CER, only the CER remained an 185 
independent prognostic variable for 5-years DFS (HR 0.393 CI 0.283-0.548, P=0.00001) and 186 
BCSS (HR 0.553 CI 0.423-0.722, P=2.506 x10
-8
). In multivariate analysis that included 187 
grade, LN, tumour size category and HER2 status, CER impaired and negative were 188 
independent prognostic variables with CER high as the indicator category for 5-years DFS 189 
(Table 2). In terms of BCSS for the entire cohort, impaired CER was not statistically 190 
significant when analysed as a categorical variable (Table 2).  191 
9 
 
In contrast in subgroup analysis performed in ER+ patients (n=319), therefore excluding CER 192 
negative patients, impaired CER was an independent marker of poor outcome for 5-years 193 
DFS and BCSS (Table 2) in multivariate analysis that included grade, LN, tumour size, HER 194 
2 status and PR status. Importantly for 5-years DFS, impaired CER was a better predictor of 195 
outcome than PR status, tumour size and tumour grade (Table 2).  196 
 197 
Validation Study Population 198 
Validation of the prognostic power of the CER was performed in 455 patients diagnosed with 199 
early invasive operable breast cancer between January 2008 and January 2009. Patient and 200 
tumour characteristics are detailed in Table 3.  201 
There were notable differences between the study cohorts. The validation cohort had fewer 202 
patients with ER negative breast cancer, and PR negative breast cancer. As expected with a 203 
more recent cohort, the majority of HER 2+ patients received biological therapy and more 204 
patients underwent breast conservation surgery. More patients had LN negative disease and 205 
were over 50 years at age, presumably as a result of improved breast screening uptake. 206 
Almost all (98%) patients with ER+ breast cancer received endocrine treatment.  207 
Median follow up was 68.25 months (5.7 years). 80% (n=364) patients were alive and well, 208 
7% (n=31) had died as a result of breast cancer and 9% (n=42) had died from other causes. 209 
4% (n=19) were alive with documented evidence of breast cancer recurrence, therefore 11 % 210 
(n=50) had a breast cancer specific event.  211 
CER classification in this cohort was associated with highly significant differences in DFS 212 
between CER negative, CER impaired and CER high groups (figure 3A). There was no 213 
significant difference in outcome between ER low and negative (figure 3B) or PR low and 214 
negative (figure 3C). The CER was a more powerful predictor of DFS than either the ER or 215 
PR. In multivariate analysis comparing the three factors the CER classification was 216 
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independently significant, CER negative HR 6.416 (CI 3.129- 13.157, P=3.903 x10
-7
) and 217 
CER impaired HR 2.627 (CI 1.327-5.202, P=0.006). In multivariate analysis that included 218 
grade, tumour size and LN (HER2 was not included as this was not significantly associated 219 
with poor outcome as most HER2+ patients received biological therapy) the CER was 220 
independently significant in the validation cohort, including ER+ subgroup (n=398) (Table 221 
2). The CER was a more powerful predictor of DFS than grade and tumour size (Table 2). 222 
Tumour size, grade and LN were independently significant for DFS as expected when 223 
included in multivariate analysis without CER (data not shown). 224 
 225 
Discussion 226 
The combined endocrine receptor (CER) is economical and an easily reproducible algorithm 227 
using well validated routinely tested biomarkers. In the derivation study for patients with 228 
early breast cancer, the CER was observed to be a better predictor of DFS and BCSS than 229 
either ER or PR alone. In addition, the CER is independently significant in multivariate 230 
analysis when combined with grade, lymph node status and tumour size. These findings were 231 
validated in a separate, modern cohort of early breast cancer patients.  232 
Semi quantitative IHC is the near universal choice of tumour hormone (ER and PR) receptor 233 
testing. Despite its widespread use there have been a number of controversies in recent years 234 
regarding hormone testing.  235 
 236 
IHC is a semi quantitative technique and pre analytical, analytical and post analytical factors 237 
can influence the results and result in test variation (Allred et al, 2009). In the derivation 238 
study expression level of both receptors were centrally tested to avoid testing variation. The 239 
validation study utilised the Allred scores from the pathology reports. The receptor testing 240 
had been performed in CPA accredited laboratories and represent ‘real world’ data.  241 
11 
 
IHC assays of ER and PR are limited to determining whether the receptors are present in 242 
tumour cells and providing some information on the levels of ER and PR in the tumour. The 243 
primary purpose of evaluating the ER and/ or PR status for individual patients is to predict 244 
whether they will respond to endocrine therapy. For the purposes of selecting endocrine 245 
therapy it is the hormone receptor status that is primarily important. It is notable however, 246 
that 6% of patients of ER negative patients were reclassified as CER impaired (ER-/PR+) in 247 
the derivation cohort and 1% in the validation cohort, suggesting that the CER categorisation 248 
will ensure more patients with hormone receptor positive disease will be considered eligible 249 
for endocrine treatment.  250 
 251 
The categorisation should be clinically useful in the context of guiding adjuvant 252 
chemotherapy. Importantly, in both cohorts a substantial number of patients with high Allred 253 
ER scores were reclassified as impaired using the CER. There is an open question regarding 254 
the importance of quantifying hormone receptor expression level by IHC. Fisher et al (2005) 255 
compared various methods of scoring ER and PR, involving percentage ranges, intensity, 256 
both summated and as a product and concluded that the ‘any-or none’ method was just as 257 
good at prediction and simpler. Certainly within our own study, the level of ER 258 
independently when analysed as negative, low and high did not have a linear relationship 259 
with outcome. However, when analysed as the combined endocrine receptor, a direct 260 
proportional benefit with outcome and level of receptors was identified. Higher amounts of 261 
hormone receptor levels as determined by IHC have been associated with improved patient 262 
outcomes (Barnes et al, 1996; Cowen et al, 1990; Dowsett et al, 2008; Elledge et al, 2000; 263 
Esteban et al, 1994; Lockwood et al, 1999; Stendahl et al, 2006; Yamashita et al, 2006). 264 
These studies suggest that patients with higher ER IHC levels will have a higher probability 265 
12 
 
of good outcome probably due to good response to endocrine therapy. Our study supports 266 
that the level of both hormone receptors is important for outcome. 267 
While the predictive power of the ER is undisputed, the predictive power and clinical utility 268 
of PR is more controversial (Hefti et al, 2013; Olivotto et al, 2004). Since 2009 the UK 269 
National Institute of Clinical Excellence (NICE) no longer recommends PR measurement in 270 
routine pathological assessment of early breast cancer (National Institute for Health and, and 271 
Excellence, 2009). A number of studies have, however, reported the prognostic power of PR 272 
(Blows et al, 2010; Purdie et al, 2014; Viale et al, 2007; Mohammed et al, 2015). Our results 273 
are in keeping these studies demonstrating improved outcome in ER+/PR+ breast cancer and 274 
support the value of PR measurement in breast cancer patients. 275 
 276 
The aim of this study was simple, combining the ER and PR will be more informative in 277 
terms of outcome than either independently. Our working hypothesis is that ER and PR 278 
should not be considered alone, both are required and semi-quantitative IHC ER and PR 279 
scores together may represent a surrogate ‘snap shot’ of functional hormone receptor 280 
crosstalk. The importance of ER and PR being functionally linked through complex crosstalk 281 
has recently been defined (Mohammed et al, 2015). To our knowledge we are the first study 282 
to report a combined ER and PR IHC. This was a retrospective study and relatively small in 283 
terms of patient numbers. We would urge for further testing and application in larger cohorts 284 
from different centres to validate this score. The cut-offs applied were based on consensus 285 
opinion of what is considered high and low receptor expression of ER and PR (Goldhirsch et 286 
al, 2009), and supported statistically to define the CER categories. Importantly, the cut-offs 287 
were robust in the validation cohort.  288 
In conclusion, the CER is a more powerful predictor of patient outcome than either the ER or 289 
PR alone and is a simple and economical method to identify risk in ER+ early breast cancer. 290 
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Title and legends to figures and tables 417 
Table 1. Characteristics of the derivation study population. 418 
For the derivation population study, patient and tumour characteristics in the column titled 419 
“total” are re-categorised according to the combined endocrine receptor (CER) classification. 420 
ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 421 
receptor 2; neg, negative; imp, impaired; hi, high. 422 
 423 
Table 2. Multivariate cox analysis for 5-year DFS and BCSS in the derivation and validation 424 
cohorts.  425 
CER, combined endocrine receptor; ER, oestrogen receptor; PR, progesterone receptor; 426 
HER2+, human epidermal growth factor receptor 2-positive; imp, impaired; neg, negative. 427 
 428 
Table 3. Characteristics of the validation study population. 429 
For the validation population study, patient and tumour characteristics in the column titled 430 
“total” are re-categorised according to the combined endocrine receptor (CER) classification. 431 
Patients received endocrine therapy in the form of tamoxifen monotherapy, aromatase 432 
inhibitor (AI) monotherapy, early switch within 5 years AI-tamoxifen or vice versa and 433 
extended switch, 5 years on AI switched to tamoxifen or vice versa. ER, oestrogen receptor; 434 
PR, progesterone receptor, HER2, human epidermal growth factor receptor 2; neg, negative; 435 
imp, impaired; hi, high. 436 
 437 
Figure 1. Determination of the cut-offs for the combined endocrine receptor (CER). 438 
Kaplan-Meier plots were constructed for all possible CER values 0, 0.5, 1, 1.5 and 2. The 439 
outcome is 5-year disease-free survival (DFS).  440 
 441 
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Figure 2. Kaplan-Meier plots in the derivation study. 442 
5-year disease-free survival (DFS) was plotted according to the combined endocrine receptor 443 
(CER) scores (A), oestrogen receptor (ER) scores (B) or progesterone receptor (PR) scores 444 
(C). Breast cancer-specific survival (BCSS) at 15-years was plotted according to CER scores 445 
(D), ER scores (E) or PR scores (F). hi, high; imp, impaired; neg, negative. 446 
 447 
Figure 3. Kaplan-Meier plots in the validation study. 448 
5-year disease-free survival (DFS) was plotted according to the combined endocrine receptor 449 
(CER) scores (A), oestrogen receptor (ER) scores (B) or progesterone receptor (PR) scores 450 
(C). hi, high; imp, impaired; neg, negative. 451 
 452 
Supplementary figure 1. CONSORT diagrams 453 
CONSORT diagrams for the derivation cohort (A) and the validation cohort (B). TMA, tissue 454 
microarray; ER, oestrogen receptor; PR, progesterone receptor; IHC, immunohistochemistry; 455 
HER2, human epidermal growth factor receptor 2. 456 
 457 
Supplementary figure 2. Immunohistochemical staining of breast specimens for ER and PR. 458 
Representative examples of negative, low (Allred score 3-5) and high (Allred score 6-8) ER 459 
and PR staining. The pictures show nuclear staining of tumour cells with intermittent stromal 460 
components. ER, oestrogen receptor; PR, progesterone receptor. 461 
  462 
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Supplementary figure 2 476 
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Tables 479 
Table 1: Characteristics of the derivation study population 
  
 
Total CERneg CERimp CERhi 
  
 
N (%) N (%) N (%) N (%) 
Age 
  < 50 144 (29) 63 (37) 43 (23) 38 (27) 
  ≥ 50 359 (71) 109 (63) 146 (77) 104 (73) 
Grade 
  1 93 (18) 3 (2) 51 (27) 39 (27) 
  2 217 (43) 33 (19) 108 (57) 76 (53) 
  3 191 (38) 134 (78) 30 (16) 27 (19) 
  unknown 2 (<1) 2 (1) 
 
  
Lymph node 
  0 287 (57) 95 (55) 109 (58) 83 (58) 
  1-3 129 (26) 39 (23) 52 (28) 38 (27) 
  > 3 81 (16) 37 (21) 26 (14) 18 (13) 
  unknown 6 (1) 1 (<1) 2 (<1) 3 (2) 
Size 
  < 20mm 297 (59) 83 (49) 121 (64) 93 (66) 
  20-50 mm 189 (38) 81 (47) 62 (33) 46 (32) 
  > 50mm 16 (3) 7 (4) 6 (3) 3 (2) 
  Unknown 1 (<1) 1 (<1) 
 
  
ER Allred score 
  < 3 184 (37) 172 (100) 12 (6)   
  3-5 56 (11) 
 
56 (30)   
  6-8 263 (52) 
 
121 (64) 142 (100) 
PR Allred score 
  < 3 281 (56) 172 (100) 109 (58)   
  3-5 57 (11) 
 
57 (30)   
  6-8 165 (33) 
 
23 (12) 142 (100) 
HER2 
  positive 76 (15) 51 (30) 16 (9) 9 (6) 
  negative 417 (83) 117 (68) 169 (89) 131 (92) 
  unknown 10 (2)  4 (2) 4 (2) 2 (2) 
Surgical operation 
  mastectomy 322 (64) 105 (61) 125 (66) 92 (65) 
  conservation 181 (36) 67 (39) 64 (34) 50 (35) 
Endocrine therapy 
  yes 368 (73) 69 (40) 170 (90) 129 (91) 
  no 127 (25) 100 (58) 16 (8) 11 (8) 
  unknown 8 (2) 3 (2) 3 (2) 2 (1) 
Chemotherapy 
  yes 208 (42) 116 (67) 49 (26) 43 (30) 
  no 292 (58) 55 (32) 138 (73) 99 (70) 
  unknown 3 (<1) 1 (<1) 2 (1)   
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Table 2: Multivariate cox analysis for 5-year DFS and 
BCSS in the derivation and validation cohorts 
  
 
Hazard ratio (CI) Significance 
Derivation cohort 
5-year DFS 
  Lymph node 1.895 (1.453 - 2.472) P=0.00005 
  Grade 1.560 (1.001- 2.431) P=0.050 
  Size 1.380 (0.918 -  2.173) P=0.121 
  CERneg 4.441 (1.895 – 10.411) P=0.001 
  CERimp 2.869 (1.240-6.639) P=0.014 
  HER2+ 1.676 (1.004-2.798) P=0.048 
BCSS 
  Lymph node 1.833 (1.428-2.353) P=0.000002 
  Grade 1.504 (1.026-2.203) P=0.036 
  Size  1.711 (1.196-2.448) P=0.003 
  CERneg 2.024 (1.065-3.848) P=0.031 
  CERimp 1.788 (0.974-3.283) P=0.061 
  HER2+ 1.182 (0.717-1.948) P=0.511 
5-year DFS in ER+ patients 
  Lymph node 2.027 (1.281-3.209) P=0.003 
  Grade 1.646 (0.899-3.012) P=0.106 
  Size 1.208 (0.639-2.35) P=0.561 
  CERimp 2.469 (1.049-5.810) P=0.038 
  PRneg 0.956 (0.409-2.236) P=0.917 
  HER2+ 4.160 (1.803-9.603) P=0.001 
BCSS ER+ patients 
  Lymph node 2.070 (1.406-3.049) P=0.0002 
  Grade 1.825 (1.167-2.855) P=0.008 
  Size 1.723 (1.167-2.806) P=0.029 
  CERimp 1.946 (1.054-3.596) P=0.033 
  PgRneg 0.928 (0.464-1.858) P=0.833 
  HER2+ 1.535 (0.644-3.629) P=0.329 
Validation cohort 
DFS 
  Lymph node 1.818 (1.282-2.579) P=0.001 
  Grade 1.266 (0.731-2.192) P=0.400 
  Size 1.416 (0.825-2.428) P=0.207 
  CERneg 5.722 (2.727-12.003) P=0.000004 
  CERimp 2.431 (1.196-4.941) P=0.014 
DFS in ER+ patients 
  Lymph node 2.388 (1.554-3.671) P=0.00007 
  Grade 1.445 (0.805-2.594) P=0.218 
  Size 1.299 (0.680-2.480) P=0.428 
  CERimp 2.096 (1.010-4.351) P=0.047 
  PRneg 0.763 (0.299-1.948) P=0.571 
 480 
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Table 3: Characteristics of the validation study population 
  
 
Total CERneg CERimp CERhi 
  
 
N (%) N (%) N (%) N (%) 
Age 
  <50 68 (15) 15 (27) 18 (12) 35 (14) 
  ≥50 387 (85) 40 (73) 130 (88) 217 (86) 
Grade 
  1 77 (17) 
 
22 (15) 55 (22) 
  2 209 (46) 5 (9) 66 (45) 138 (55) 
  3 168 (37) 50 (91) 60 (40) 58 (23) 
  unknown 1 (<1) 
  
1 (<1) 
Lymph node 
  0 311 (68) 36 (66) 94 (64) 181 (72) 
  1-3 97 (21) 11 (20) 31 (21) 55 (22) 
  >3 46 (10) 8 (14) 23 (15) 15 (6) 
  unknown 1 (<1) 
  
1 (<1) 
Size 
  <20 mm 254 (56) 18 (33) 74 (51) 162 (64) 
  20-50 mm 176 (39) 35 (64) 61 (41) 80 (32) 
  >5 mm 13 (3) 2 (3) 8 (5) 3 (1) 
  unknown 12 (3) 
 
5 (3) 7 (3) 
ER Allred score 
  <3 57 (12) 55 (100) 2 (1)   
  3-5 21 (5) 
 
21 (14)   
  6-8 377 (83) 
 
125 (85) 
252 
(100) 
PR Allred score 
  <3 111 (24) 55 (100) 56 (38)   
  3-5 90 (20) 
 
90 (61)   
  6-8 254 (56) 
 
2 (1) 
252 
(100) 
HER2 
  positive 70 (15) 18 (33) 35 (24) 17 (7) 
  negative 382 (84) 37 (67) 111 (75) 234 (93) 
  unknown 3 (<1) 
 
2 (1) 1 (<1) 
Surgical operation 
  mastectomy 131 (29) 24 (44) 44 (30) 63 (25) 
  conservation 324 (72) 31 (56) 104 (70) 189 (75) 
Endocrine therapy 
  yes 392 (86) 2 (4) 140 (95) 250 (99) 
  tamoxifen 184 (40) 
 
57 (39) 127 (50) 
  AI 138 (30) 2 (4) 57 (39) 79 (31) 
  early switch 46 (10) 
 
14 (9) 32 (12) 
  late switch 24 (5) 
 
12 (8) 12 (5) 
  no 63 (14) 53 (96) 8 (5) 2 (<1) 
Chemotherapy 
29 
 
  yes 166 (37) 40 (73) 59 (40) 67 (27) 
  no 289 (63) 15 (27) 89 (60) 185 (73) 
Biological therapy 
  yes 50 (11) 14 (25) 24 (16) 12 (5) 
  no 405 (89) 41 (75) 124 (84) 240 (95) 
 481 
